# Switching Study From Warfarin to Rivaroxaban

> **NCT01507051** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 96 (actual)

## Conditions studied

- Venous Thrombosis

## Interventions

- **DRUG:** Warfarin (Coumadin)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Placebo
- **DRUG:** Vitamin K (Konakion)

## Key facts

- **NCT ID:** NCT01507051
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2015-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01507051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01507051, "Switching Study From Warfarin to Rivaroxaban". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01507051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*